Literature DB >> 17245117

Polyclonal tumors in the mammalian intestine: are interactions among multiple initiated clones necessary for tumor initiation, growth, and progression?

Richard B Halberg1, William F Dove.   

Abstract

Studies in both man and mouse indicate that the majority of familial intestinal tumors are polyclonal being composed of cells from at least two distinct progenitors. The formation of polyclonal tumors in the mouse can be explained by short-range interactions between multiple initiated clones within one or two crypt diameters of each other. These clonal interactions might be critical, if not necessary, for initiation, growth, progression, or all three stages of tumorigenesis. This view is diametrically opposed to the widely held view that intestinal tumors are monoclonal and progress by clonal expansion. The data supporting the latter are neither extensive nor definitive. In addition, the results from a recent study indicate that earlier studies of tumor clonality were heavily biased because lineage patches in the intestinal epithelium of humans resulting from X-inactivation are relatively large. Consequently, hundreds of tumors from familial and sporadic cases need to be analyzed to accurately assess tumor clonality. Investigators must keep an open mind regarding the clonality of tumors in the mammalian intestine as new experimental approaches are developed which will eventually provide a definitive answer to this fundamental question in the field of cancer biology.

Entities:  

Mesh:

Year:  2007        PMID: 17245117      PMCID: PMC2390772          DOI: 10.4161/cc.6.1.3651

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  64 in total

1.  Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse.

Authors:  Lara S Collier; Corey M Carlson; Shruthi Ravimohan; Adam J Dupuy; David A Largaespada
Journal:  Nature       Date:  2005-07-14       Impact factor: 49.962

2.  The receptor for epidermal growth factor is present in human fetal kidney, liver and lung.

Authors:  E Nexø; N Kryger-Baggesen
Journal:  Regul Pept       Date:  1989-08

Review 3.  Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma.

Authors:  Alan P Venook
Journal:  Cancer       Date:  2005-06-15       Impact factor: 6.860

4.  Molecular staging for survival prediction of colorectal cancer patients.

Authors:  Steven Eschrich; Ivana Yang; Greg Bloom; Ka Yin Kwong; David Boulware; Alan Cantor; Domenico Coppola; Mogens Kruhøffer; Lauri Aaltonen; Torben F Orntoft; John Quackenbush; Timothy J Yeatman
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

5.  Value of genetic variants of glucose-6-phosphate dehydrogenase in tracing the origin of malignant tumors.

Authors:  E Beutler; Z Collins; L E Irwin
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

6.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors:  S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

7.  X-inactivation patch size in human female tissue confounds the assessment of tumor clonality.

Authors:  Marco Novelli; Antonio Cossu; Dahmane Oukrif; Alberto Quaglia; Sunil Lakhani; Richard Poulsom; Peter Sasieni; Piera Carta; Marcella Contini; Anna Pasca; Giuseppe Palmieri; Walter Bodmer; Francesco Tanda; Nick Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-27       Impact factor: 11.205

8.  Clonal analysis of human colorectal tumors.

Authors:  E R Fearon; S R Hamilton; B Vogelstein
Journal:  Science       Date:  1987-10-09       Impact factor: 47.728

9.  The clonal origin of experimental large bowel tumours.

Authors:  D F Griffiths; P Sacco; D Williams; G T Williams; E D Williams
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

10.  Development of the pattern of cell renewal in the crypt-villus unit of chimaeric mouse small intestine.

Authors:  G H Schmidt; D J Winton; B A Ponder
Journal:  Development       Date:  1988-08       Impact factor: 6.868

View more
  7 in total

1.  Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention.

Authors:  Jared M Fischer; Arnout G Schepers; Hans Clevers; Darryl Shibata; R Michael Liskay
Journal:  Carcinogenesis       Date:  2013-08-29       Impact factor: 4.944

Review 2.  Passenger mutations as a marker of clonal cell lineages in emerging neoplasia.

Authors:  Jesse J Salk; Marshall S Horwitz
Journal:  Semin Cancer Biol       Date:  2010-10-15       Impact factor: 15.707

Review 3.  An evolutionary perspective on field cancerization.

Authors:  Kit Curtius; Nicholas A Wright; Trevor A Graham
Journal:  Nat Rev Cancer       Date:  2017-12-08       Impact factor: 60.716

4.  Widespread hyperplasia induced by transgenic TGFalpha in ApcMin mice is associated with only regional effects on tumorigenesis.

Authors:  Andrea Bilger; Ruth Sullivan; Amy J Prunuske; Linda Clipson; Norman R Drinkwater; William F Dove
Journal:  Carcinogenesis       Date:  2008-02-28       Impact factor: 4.944

5.  Tissue architecture delineates field cancerization in BRAFV600E-induced tumor development.

Authors:  Elin Schoultz; Ellen Johansson; Carmen Moccia; Iva Jakubikova; Naveen Ravi; Shawn Liang; Therese Carlsson; Mikael Montelius; Konrad Patyra; Jukka Kero; Kajsa Paulsson; Henrik Fagman; Martin O Bergo; Mikael Nilsson
Journal:  Dis Model Mech       Date:  2021-08-11       Impact factor: 5.758

Review 6.  The Unfolded Protein Response at the Tumor-Immune Interface.

Authors:  Maurizio Zanetti; Su Xian; Magalie Dosset; Hannah Carter
Journal:  Front Immunol       Date:  2022-02-14       Impact factor: 7.561

7.  Comparative genomic analysis of primary and synchronous metastatic colorectal cancers.

Authors:  Sun Young Lee; Farhan Haq; Deokhoon Kim; Cui Jun; Hui-Jong Jo; Sung-Min Ahn; Won-Suk Lee
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.